SCHEMBL6718273

SCHEMBL6718273

COc1ccc(OC)c(S(=O)(=O)Nc2ccc(C3=NCCc4ccccc43)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
ALOX12 P18054 1/20 0.57
ALPL P05186 6/20 0.56
SMN1; SMN2 Q16637 4/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
ALDH1A1 P00352 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
BRD4 O60885 1/20 0.49
BRD2 P25440 1/20 0.49
BRD3 Q15059 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
TP53 P04637 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6724989 0.89 TP53 (0.54) LMNAKMT2AMEN1ALOX12ALPL
SCHEMBL6714796 0.88 SMN1; SMN2 (0.53) LMNAKMT2AMEN1ALOX12ALPL
SCHEMBL7210287 0.88 CA1 (0.54) LMNAKMT2AMEN1ALOX12ALPL
SCHEMBL6718356 0.82 TP53 (0.53) ALPLSMN1; SMN2ALDH1A1NPSR1TP53
SCHEMBL6724741 0.80 TP53 (0.53) ALPLSMN1; SMN2CA1CA2CA7
SCHEMBL6716920 0.80 SMN1; SMN2 (0.61) LMNAKMT2AALPLSMN1; SMN2ALDH1A1
SCHEMBL6725304 0.80 SMN1; SMN2 (0.61) LMNAKMT2AALPLSMN1; SMN2CA1
SCHEMBL12567716 0.77 ALDH1A1 (0.65) LMNACA1CA2CA7CA9
SCHEMBL29498350 0.77 ALDH1A1 (0.65) LMNACA1CA2CA7CA9
SCHEMBL29498357 0.77 ALDH1A1 (0.65) LMNACA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A LMNA 1790/4885KMT2A 2851/4885MEN1 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.